Relationship of teicoplanin MICs to treatment failure in teicoplanin-treated patients with methicillin-resistant Staphylococcus aureus pneumonia

Journal of Microbiology, Immunology and Infection

Volumn 46, Issue 3, 2013, Pages 210-216

  Chen, Ke Yuan ^a   Chang, Hong Jyun ^a   Hsu, Po Chang ^a   Yang, Chien Chang ^a   Chia, Ju Hsin ^a,b   Wu, Tsu Lan ^a,b   Huang, Ching Tai ^a   Lee, Ming Hsun ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

MRSA; Pneumonia; Teicoplanin

Indexed keywords

TEICOPLANIN;

ADULT; AGED; ARTICLE; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; PREDICTIVE VALUE; PULMONARY ASPIRATION; RISK FACTOR; SPUTUM CULTURE; TREATMENT FAILURE; TREATMENT OUTCOME;

DRUG RESISTANCE, BACTERIAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, STAPHYLOCOCCAL; PROGNOSIS; SPUTUM; TEICOPLANIN; TRACHEA; TREATMENT FAILURE;

EID: 84879273899     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2012.06.010     Document Type: Article

References (30)

1. Haessler S.D., Brown R.B. Pneumonia caused by Staphylococcus aureus. Curr Respir Med Rev 2009, 5:62-67.
2. Rello J., Torres A., Ricart M., Valles J., Gonzalez J., Artigas A., et al. Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 1994, 150:1545-1549.
3. González C., Rubio M., Romero-Vivas J., González M., Picazo J.J. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999, 29:1171-1177.
4. Lentino J.R., Hennein H., Krause S., Pappas S., Fuller G., Schaaff D., et al. A comparison of pneumonia caused by gentamicin, methicillin-resistant and gentamicin, methicillin-sensitive Staphylococcus aureus: epidemiologic and clinical studies. Infect Control 1985, 6:267-272.
5. Combes A., Luyt C.E., Fagon J.Y., Wollf M., Trouillet J.L., Gibert C., et al. Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia. Am J Respir Crit Care Med 2004, 170:786-792.
6. Karchmer A.W. Staphylococcus aureus and vancomycin: the sequel. Ann Intern Med 1991, 115:739-741.
7. Wunderink R.G., Rello J., Cammarata S.K., Croos-Dabrera R.V., Kollef M.H. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003, 124:1789-1797.
8. Lamer C., de Beco V., Soler P., Calvat S., Fagon J.Y., Dombret M.C., et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993, 37:281-286.
9. Haque N.Z., Zuniga L.C., Peyrani P., Reyes K., Lamerato L., Moore C.L., et al. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest 2010, 138:1356-1362.
10. Chang H.J., Hsu P.C., Yang C.C., Siu L.K., Kuo A.J., Chia J.H., et al. Influence of teicoplanin MICs on treatment outcomes among patients with teicoplanin-treated methicillin-resistant Staphylococcus aureus bacteraemia: a hospital-based retrospective study. J Antimicrob Chemother 2012, 67:736-741.
11. American Thoracic Society; Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416.
12. Ye J.J., Lin H.S., Kuo A.J., Leu H.S., Chiang P.C., Huang C.T., et al. The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii. J Infect 2011, 63:351-361.
13. Pugin J., Auckenthaler R., Mili N., Janssens J.P., Lew P.D., Suter P.M. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis 1991, 143:1121-1129.
14. Tablan O.C., Anderson L.J., Besser R., Bridges C., Hajjeh R. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004, 53:1-36.
15. Niederman M.S. Guidelines for the management of respiratory infection: why do we need them, how should they be developed, and can they be useful?. Curr Opin Pulm Med 1996, 2:161-165.
16. Craven D.E., Kunches L.M., Kilinsky V., Lichtenberg D.A., Make B.J., McCabe W.R. Risk factors for pneumonia and fatality in patients receiving continuous mechanical ventilation. Am Rev Respir Dis 1986, 133:792-796.
17. Hutt E., Kramer A.M. Evidence-based guidelines for management of nursing home-acquired pneumonia. J Fam Pract 2002, 51:709-716.
18. Mylotte J.M. Nursing home-acquired pneumonia. Clin Infect Dis 2002, 35:1205-1211.
19. Vincent J.L., Moreno R., Takala J., Willatts S., De Mendonça A., Bruining H., et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22:707-710.
20. Bannerman T.L., Peacock S.J. Staphylococcus, Micrococcus, and other catalase-positivecocci. Manual of clinical microbiology 2007, 390-411. American Society of Microbiology, Washington, DC. 9th ed. P.R. Murray, E.J. Baron, J.H. Jorgensen, M.A. Pfaller, R.H. Yolken (Eds.).
21. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement M100-S21 2011, USA.
22. European Committee on Antimicrobial Susceptibility Testing EUCAST Clinical Breakpoint 2011-01-05, Table v. 1.3, Available from:, [accessed 1.02.12]. http://www.eucast.org/clinical_breakpoints/.
23. Kollef M.H., Sherman G., Ward S., Fraser V.J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462-474.
24. Chan Y.Y., Lin T.Y., Huang C.T., Deng S.T., Wu T.L., Leu H.S., et al. Implementation and outcomes of a hospital-wide computerised antimicrobial stewardship programme in a large medical centre in Taiwan. Int J Antimicrob Agents 2011, 38:486-492.
25. Charlesworth R., Warner M., Livermore D.M., Wilson A.P. Comparison of four methods for detection of teicoplanin resistance in methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006, 58:186-189.
26. Soriano A., Marco F., Martinez J.A., Pisos E., Almela M., Dimova V.P., et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008, 46:193-200.
27. Lodise T.P., Graves J., Evans A., Graffunder E., Helmecke M., Lomaestro B.M., et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008, 52:3315-3320.
28. Wang J.L., Wang J.T., Sheng W.H., Chen Y.C., Chang S.C. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC=2mg/L, by the broth microdilution method. BMC Infect Dis 2010, 10:159.
29. Khatib R., Jose J., Musta A., Sharma M., Fakih M.G., Johnson L.B., et al. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2011, 66:1594-1599.
30. Wang J.T., Liao H.I., Wu Lin F.L., Chang S.C. Loading dose required to achieve rapid therapeutic teicoplanin trough plasma concentration in patients with multidrug-resistant gram-positive infections. Basic Clin Pharmacol Toxicol 2011, 110:416-420.